News | February 08, 2022
GlaxoSmithKline Pharmaceuticals delivers strong financials in Q3FY22
EBITDA from Continuing Operations at Rs. 582 crore recorded a growth of 31 %.
EBITDA from Continuing Operations at Rs. 582 crore recorded a growth of 31 %.
Newly formed Life Science Services business unit to offer fully integrated CDMO and Contract Testing Services
Granules India has reported consolidated financial results for the period ended December 31, 2021
Aster DM Healthcare has reported consolidated financial results for the period ended December 31, 2021
Suven Pharmaceuticals has reported consolidated financial results for the period ended December 31, 2021.
Arformoterol Tartrate had estimated annual sales of US $ 251 million in the U.S. (IQVIA MAT December 2021)
Biosynthetic Technologies produces estolides, a new class of biobased synthetic oils used in a number of applications, including motor oil, industrial lubricants, pharmaceuticals, and personal care.
Rapid testing produces air sample results in 30 minutes
Under the terms of the agreement, Biogen will make an upfront payment of US $ 8 million to Xbrane
This is the ninth Covid-19 vaccine approved in India
Subscribe To Our Newsletter & Stay Updated
